

CVS Health & Walgreens COVVAXAGE Linked Cohort

54AG063546-S07 & U54AG063546-S08



Geographic variation in bivalent COVID-19 vaccinations among older adults with Alzheimer's disease and related dementias



Daniel A. Harris, Kaleen N. Hayes, Preeti Chachlani, Katherine J. Wen, Vincent Mor, Ellen P. McCarthy



OBJECTIVE: To measure the uptake of bivalent COVID-19 vaccines in a national sample of older adults with ADRD and assess for variation in uptake by geography and frailty level.



STUDY DESIGN, DATA SOURCE, AND PARTICIPANTS:

- Cohort study between August 28, 2022 (study index date) to March 31, 2023
- COVVAXAGE linked cohort (75% of Medicare beneficiaries ≥ 65 years of age)
- Community-dwelling Medicare fee-for-service (FFS) beneficiaries with ADRD
 - ADRD was defined using the 1-year Bynum algorithm based on Medicare claims



MEASURES AND ANALYSIS:


- Outcome: Bivalent COVID-19 vaccinations were identified using Medicare Part B
- Censoring criteria: Death, long-term care/hospice admission, or administrative end of follow-up (March 31, 2023)
- Subgroups:
 - National Center for Health Statistics' classification for rural/urban counties
 - Kim claim's-based frailty index (non-frail [CFI < 0.15]; pre-frail [0.15≤CFI <0.25]; frail [≥ 0.25])
- Statistical analysis: Kaplan-Meier estimates of absolute vaccination uptake; Cox proportional hazards models for relative uptake rates by frailty and urbanicity




RESULTS:

Population characteristics (N=893,060)

■ Black ■ Hispanic ■ Other or missing ■ White




Absolute vaccination rates



OVERALL RATE = 32.1%

Relative vaccination rates





RELEVANCE: We observed low uptake of the bivalent COVID-19 vaccine among persons with ADRD, especially those living in rural areas.